diazoxide

SRG-95213

Proglycem

3-methyl-7-chloro-1,2,4-benzothiadiazine 1,1-dioxide

A benzothiadiazine derivate with antihypertensive and hyperglycemic activities. Diazoxide increases membrane permeability to potassium ions in vascular smooth muscle, thereby stabilizing the membrane action potential and preventing vascular smooth muscle contraction; this results in peripheral vasodilatation and decreases in peripheral vascular resistance. This agent also inhibits insulin release by interacting with ATP-sensitive potassium channels of pancreatic islet beta-cells. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C428" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C428" NCI Thesaurus)

http://purl.bioontology.org/ontology/PDQ/CDR0000039290

SRG-95213

Proglycem

3-methyl-7-chloro-1,2,4-benzothiadiazine 1,1-dioxide

C0699325

C1711242

C0012022

2008-10-02

A benzothiadiazine derivate with antihypertensive and hyperglycemic activities. Diazoxide increases membrane permeability to potassium ions in vascular smooth muscle, thereby stabilizing the membrane action potential and preventing vascular smooth muscle contraction; this results in peripheral vasodilatation and decreases in peripheral vascular resistance. This agent also inhibits insulin release by interacting with ATP-sensitive potassium channels of pancreatic islet beta-cells. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C428" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C428" NCI Thesaurus)

1923

TRD

C428

CDR0000039290

76130

64198

Drug/agent

diazoxide

T109

T121